Financial Performance - The company's operating revenue for 2024 was ¥173,532,721.07, a decrease of 51.83% compared to ¥360,253,871.23 in 2023[21]. - The net profit attributable to shareholders for 2024 was ¥6,975,282.60, down 95.68% from ¥161,553,919.38 in 2023[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥3,891,951.20, a decline of 97.58% from ¥161,065,688.52 in 2023[21]. - The net cash flow from operating activities for 2024 was ¥39,437,023.16, a decrease of 54.44% compared to ¥86,554,073.66 in 2023[21]. - The total assets at the end of 2024 were ¥1,447,992,684.90, down 7.97% from ¥1,573,359,475.20 at the end of 2023[21]. - The net assets attributable to shareholders at the end of 2024 were ¥1,405,020,800.85, a decrease of 4.08% from ¥1,464,836,602.87 at the end of 2023[21]. - Basic and diluted earnings per share dropped to 0.03 yuan per share, a decline of 97.06% from 1.02 yuan per share in 2023[22]. - The weighted average return on equity fell to 0.49%, a decrease of 11.29 percentage points from 11.78% in 2023[22]. Research and Development - The company emphasizes the importance of its R&D efforts in developing new drug formulations and technologies[11]. - Research and development investment as a percentage of operating revenue increased by 6.23 percentage points[23]. - The company has increased R&D investment, focusing on expanding the indications for injectable paclitaxel polymer micelles, with ongoing phase III clinical trials for breast cancer and pancreatic cancer[41]. - The company has developed two new drugs: a multifunctional monoclonal antibody YXC-001 and a small molecule targeted drug YXC-002, both of which are in preclinical research[36]. - R&D expenses rose significantly by 65.71% to ¥37,203,747.41, indicating a strong focus on innovation[149]. - The company has maintained a stable R&D team without any core personnel turnover during the reporting period[109]. - The company is actively expanding clinical trials for its core product, paclitaxel micelles, to increase the number of registered indications[109]. Product Development and Market Strategy - The company’s core product, paclitaxel polymer micelles, continues to be a key focus in its product lineup[11]. - The core product, paclitaxel micelles, was successfully included in the national medical insurance directory, which is expected to enhance market promotion and sales[37]. - The company is preparing for the 2024 medical insurance negotiations for its core product, engaging third-party experts for guidance and research[34]. - The company aims to adapt quickly to external changes while ensuring safe and steady development[30]. - The company is focused on building a strong brand image centered on clinical value, product quality, and technological innovation[184]. - The company is expanding its marketing team and implementing performance assessment and incentive mechanisms to improve overall performance and employee engagement[82]. - The company is leveraging digital marketing strategies to enhance drug accessibility and optimize channel inventory management[82]. Operational Challenges and Risks - The company has not faced any significant risks that could materially impact its operations during the reporting period[4]. - The company experienced significant challenges in marketing its core product due to difficulties in market access and changes in the pharmaceutical industry environment[30]. - The company's future operational plans and development strategies are subject to risks and do not constitute substantive commitments to investors[6]. - The rapid development of new cancer therapies, including targeted and immunotherapies, poses a risk to the company's existing and pipeline products if more effective treatments emerge[133]. - The company must adapt to regulatory changes in the healthcare system, as price declines in drug procurement could negatively impact sales revenue and net profit[134]. Corporate Governance and Management - The company has maintained a standard unqualified audit opinion from its accounting firm, ensuring the accuracy of its financial reports[5]. - The company’s management has committed to ensuring the authenticity and completeness of the annual report[5]. - The company has not engaged in any non-operational fund occupation by controlling shareholders or related parties[7]. - The company has held 5 board meetings and 4 supervisory meetings during the reporting period, ensuring compliance with legal and regulatory requirements[189]. - The company is committed to enhancing its internal control systems and governance structure to support high-quality development[186]. Market Trends and Industry Outlook - The global pharmaceutical market is projected to reach $1.5 trillion in 2023, with a CAGR of 3%-6% from 2023 to 2027, driven by innovative drugs related to oncology and immunotherapy[84]. - China's pharmaceutical market is expected to grow from approximately $165 billion in 2022 to $195 billion in 2024, with increasing demand in oncology, diabetes, and chronic disease sectors[86]. - The global oncology drug market was valued at $150.3 billion in 2020 and is expected to grow to $304.8 billion by 2025, reflecting a CAGR of 15.2%[90]. - The company is positioned to benefit from the ongoing reforms in the healthcare system, which are expected to create new growth opportunities in the pharmaceutical industry[158]. Shareholder Information - The total number of shares held by the chairman and general manager, Zhou Jinsong, increased from 33,531,344 to 43,590,747, reflecting a change of 10,059,403 shares due to the implementation of the capital reserve conversion into share capital plan[194]. - The total number of shares held by the company’s board members and senior management increased from 41,129,494 to 53,554,342, a total increase of 12,424,848 shares[196]. - The total pre-tax remuneration for Zhou Jinsong in the reporting period was 150.12 million yuan, with no remuneration received from related parties[194]. - The total pre-tax remuneration for the board members and senior management in the reporting period amounted to 594.67 million yuan[196].

Financial Performance - The company's revenue for Q1 2025 was ¥71,032,214.87, representing a year-on-year increase of 3.39% compared to ¥68,702,991.41 in the same period last year[5] - Net profit attributable to shareholders decreased by 51.38% to ¥14,185,975.54 from ¥29,178,031.68 in the previous year[5] - The basic earnings per share decreased by 61.11% to ¥0.07 from ¥0.18 in the same period last year[5] - Net profit for Q1 2025 was ¥14,185,975.54, a decrease of 51.5% from ¥29,178,031.68 in Q1 2024[20] - Basic and diluted earnings per share for Q1 2025 were both ¥0.07, down from ¥0.18 in Q1 2024[20] Cash Flow - The net cash flow from operating activities was negative at -¥35,461,931.24, a decline of 222.80% compared to ¥28,877,820.51 in the same period last year[5] - Cash flow from operating activities in Q1 2025 was negative at -¥35,461,931.24, compared to a positive cash flow of ¥28,877,820.51 in Q1 2024[22] - Cash inflow from investment activities in Q1 2025 was ¥2,265,244,086.29, significantly higher than ¥327,424,747.27 in Q1 2024[22] - The company reported a net cash outflow from investment activities of -¥13,182,738.71 in Q1 2025, compared to a net inflow of ¥15,609,268.37 in Q1 2024[22] - The net cash flow from financing activities was $2,588,963.52, compared to $8,805,402.79 in the previous period[23] - The net increase in cash and cash equivalents was a decrease of $46,055,706.43, contrasting with an increase of $53,292,491.67 previously[23] - The ending balance of cash and cash equivalents stood at $598,350,982.88, down from $963,178,159.26 at the beginning of the period[23] Research and Development - Research and development expenses totaled ¥9,276,624.21, an increase of 65.78% from ¥5,595,803.86 in the previous year, accounting for 13.06% of revenue[6] - Research and development expenses increased to ¥9,276,624.21 in Q1 2025, compared to ¥5,595,803.86 in Q1 2024, reflecting a growth of 65.5%[19] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,466,791,387.83, a slight increase of 1.30% from ¥1,447,992,684.90 at the end of the previous year[6] - The total assets of the company are ¥1,466,791,387.83, compared to ¥1,447,992,684.90 at the end of 2024, indicating an increase[15] - The total liabilities as of March 31, 2025, are ¥40,773,311.62, compared to ¥39,446,131.43 at the end of 2024[15] - Total liabilities increased to ¥44,115,058.89 in the latest reporting period, compared to ¥42,971,884.05 previously[16] - The total non-current assets amount to ¥694,171,916.47, an increase from ¥671,785,597.36 at the end of 2024[15] Shareholder Information - Total number of common shareholders at the end of the reporting period is 6,144[10] - The largest shareholder, Zhou Jinsong, holds 40,127,058 shares, representing 19.41% of total shares[10] - The company has a total of 24,703,546 shares held by Shanghai Kaibao Pharmaceutical Co., Ltd., representing 11.95% of total shares[11] - The company has no significant changes in the participation of major shareholders in margin trading and securities lending[12] Operational Performance - The company reported a 348% increase in sales volume of its core product, paclitaxel micelles, which was included in the medical insurance list[8] - Total operating revenue for Q1 2025 reached ¥71,032,214.87, an increase of 3.86% compared to ¥68,702,991.41 in Q1 2024[18] - Total operating costs for Q1 2025 were ¥53,585,184.88, up 44.73% from ¥36,997,180.69 in Q1 2024[18] - The company experienced increased costs in raw material procurement, marketing expenses, and R&D investments, impacting overall profitability[8] Equity - Total equity attributable to shareholders rose to ¥1,422,676,328.94 from ¥1,405,020,800.85, indicating a growth of 1.25%[16] Accounting Standards - The company will not apply new accounting standards starting from 2025[23]

上海谊众公告，2024年营业收入1.74亿元，同比减少51.83%。归属于上市公司股东的净利润697.53万 元，同比减少95.68%。基本每股收益0.03元／股，同比减少97.06%。2024年度公司拟定不再实施现金分 红或转增股本等权益分派方案。 ...

医药板块持续走高 众生药业等多股涨停 智通财经4月22日电，午后医药板块持续走高，创新药方向继续领涨，众生药业、华森制药、富士莱涨 停，百利天恒、诺诚健华、新诺威、百济神州创历史新高，复旦张江、上海谊众、信立泰、热景生物等 涨幅靠前。消息面上，4月25日至4月30日，美国癌症研究协会（AACR）年会将在芝加哥召开。作为全 球规模最大的癌症研究会议之一，AACR年会一直是癌症领域最新研究成果的重要展示平台。 ...

证券代码：688091 证券简称：上海谊众 公告编号：2025-007 上海谊众药业股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 截至 2025 年 3 月 25 日，股东上海谊兴已通过集中竞价的交易方式减持公司 股份合计 970,112 股，占公司总股本的 0.46%。 公司控股股东、实际控制人周劲松先生未参与本次减持计划。 本次权益变动为上海谊众药业股份有限公司（以下简称"公司"）股东上海谊 兴企业管理合伙企业（有限合伙）（以下简称"上海谊兴"）履行此前所披露 的减持股份计划所致，不触及要约收购，不会导致公司控股股东及实际控制 人发生变化。 本次权益变动后，公司股东上海谊兴及其一致行动人上海杉元企业管理合伙 企业（有限合伙）（以下简称"上海杉元"）、公司控股股东与实际控制人周劲 松先生合计持有股份从 54,713,058 股减少至 53,742,946 股，持股比例由 26.46%减少至 26.00%，权益变动触及 1%的整数倍。 公司于 2025 年 2 月 26 日在上海证券交易所网 ...

证券代码：688091 证券简称：上海谊众 公告编号：2025-006 上海谊众药业股份有限公司 2022 年限制性股票激励计划第一个归属期 预留授予部分股票归属结果暨股份上市公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为股权激励股份；股票认购方式为网下，上市股数为 114,400 股。 本次股票上市流通总数为 114,400 股。 本次股票上市流通日期为 2025 年 3 月 12 日。 上海谊众药业股份有限公司（以下简称"公司"）于 2025 年 3 月 6 日收到中国 证券登记结算有限责任公司上海分公司出具的《证券变更登记证明》，公司已完成 2022 年限制性股票激励计划第一个归属期预留授予部分股权归属登记的相关工作。 本次完成归属登记并上市流通的股份总数为 114,400 股，认购方式为网下，上市流 通日期为 2025 年 3 月 12 日。详情如下： 一、 限制性股票激励计划已履行的决策程序及信披情况 1、2022 年 11 月 28 日，公司召开第一届董事会第十六次会议 ...

证券代码：688091 证券简称：上海谊众 公告编号：2025-005 上海谊众药业股份有限公司 关于变更持续督导保荐代表人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海谊众药业股份有限公司（以下简称"公司"）于近日收到国金证券股份有 限公司（以下简称"国金证券"）发来的《关于变更持续督导保荐代表人的函》。 国金证券作为公司 2021 年首次公开发行股票并在科创板上市的保荐机构，担任 公司首次公开发行股票并上市项目持续督导工作的保荐代表人朱玉华女士因工 作变动，不再负责公司首次公开发行股票并上市项目的持续督导工作。为保证公 司持续督导工作的正常进行，国金证券现委派秦勤女士（简历后附）接替朱玉华 女士，担任公司持续督导保荐代表人，继续履行持续督导的保荐职责。 此次变更后，公司首次公开发行股票并上市项目持续督导保荐代表人为顾兆 廷先生和秦勤女士。 公司董事会对朱玉华女士为公司首次公开发行股票并上市及持续督导期间 所做出的贡献表示衷心的感谢！ 上海谊众药业股份有限公司董事会 2025 年 3 月 1 日 附件：秦勤 ...

Financial Performance - The total revenue for 2024 was RMB 173,825,025.22, a decrease of 51.75% compared to RMB 360,253,871.23 in the previous year[4] - The net profit attributable to the parent company was RMB 6,850,041.02, down 95.76% from RMB 161,553,919.38 in the same period last year[4] - The basic earnings per share decreased to RMB 0.03, a decline of 97.06% from RMB 1.02 in the previous year[4] Assets and Equity - Total assets at the end of the reporting period were RMB 1,448,233,847.64, a decrease of 7.95% from the beginning of the period[4] - The company's equity attributable to the parent company was RMB 1,404,895,559.27, down 4.09% from the beginning of the period[4] Product Performance and Strategy - The company’s core product, paclitaxel micelles, saw a significant decline in sales, impacting revenue and profit[7] - The company increased its investment in nationwide sales layout to promote the core product after it was included in the medical insurance directory, affecting profits[7] - The company has completed the network access in all provinces and municipalities, and the paclitaxel micelles have entered the dual-channel management directory in over 20 provinces[8] Capital and Financial Reporting - The company’s share capital increased by 30.52% due to the implementation of a capital reserve conversion plan and the completion of the first vesting period of the 2022 equity incentive plan[9] - The financial data presented are preliminary and subject to change upon the release of the audited annual report[10]

证券代码：688091 证券简称：上海谊众 公告编号：2025-003 上海谊众药业股份有限公司股东 集中竞价减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 股东持股的基本情况 截至本公告披露日，上海谊众药业股份有限公司（以下简称"公司"）股东 上海谊兴企业管理合伙企业（有限合伙）（以下简称"上海谊兴"）持有公司股份 4,862,000 股，占公司总股本的 2.35%。 上述股份来源为公司首次公开发行前及实施资本公积转增股本取得的股份， 且已于 2024 年 9 月 10 日解除限售并上市流通。 集中竞价减持计划的主要内容 公司股东上海谊兴拟通过集中竞价的交易方式减持所持有的公司股份合计 不超过 2,065,892 股，不超过公司总股本的 1%。 本次减持计划拟通过集中竞价方式进行，自本公告披露之日起 15 个交易日 后的 3 个月内进行，减持股份总数不超过公司股份总数的 1%，且在窗口期等不 得减持期间不减持。 减持价格按市场价格确定。若公司在上述减持计划实施期间发生送股、资 ...

Financial Performance - The company expects a net profit attributable to shareholders of the parent company for 2024 to be between 8 million and 10 million yuan, representing a decrease of 93.81% to 95.05% compared to the previous year[4] - The net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, is projected to be between 4 million and 6 million yuan, a decrease of 96.28% to 97.52% year-on-year[4] - The previous year's net profit attributable to shareholders of the parent company was 161.55 million yuan, and the net profit excluding non-recurring gains and losses was 161.07 million yuan[6] Product Sales and Market Access - The core product, paclitaxel polymer micelles, faced significant sales impact due to difficulties in hospital access and pharmacy configuration before entering the medical insurance directory[12] - The paclitaxel micelles were officially included in the medical insurance directory in January 2025, which will require price compensation for distributor inventory, directly affecting sales revenue and profit[12] - Following successful negotiations for medical insurance, the company has increased its investment in national sales layout, completing network access in all provinces and municipalities[12] - The paclitaxel micelles have entered the dual-channel management directory and separate payment list in over 20 provinces, with active hospital access work ongoing nationwide[12]